Dovydas Širvinskas

Dr. Dovydas Širvinskas

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DŠDovydas Širvinskas
Dovydas Širvinskas
SJSukanta Jash
Sukanta Jash
Induced pluripotent stem cells (iPSCs) have revolutionized the research landscape for Alzheimer's disease (AD) and related dementias by providing human, patient-specific neuronal models for studying the genetic and phenotypic diversity of these disorders. This review aims to integrate the latest advances in iPSC-based modeling of AD and dementia across multiple levels of biological organization. After describing the principles of pluripotency, iPSC generation, and quality control (genetic integrity, pluripotency assessment, long-term stability) the review will compare 2D monolayer culture with 3D organoid-based systems regarding their ability to model amyloid-beta, tau, and neuroinflammatory aspects of AD and dementia. The development of global stem cell biobanks and large iPSC collections with genetic diversity will be highlighted as an essential tool for dissecting the complex interplay of multiple genetic risk factors, ethnicity-based differences, and genotype-phenotype correlations. The review will discuss the use of genome editing technology, such as CRISPR/Cas9, for studying the effect of specific AD risk and protective variants in neurons and glial cells, and their implications for cell type-specific roles in neurodegeneration and neuroinflammation. We will highlight the challenges and limitations of iPSCs, such as cellular immaturity, loss of aging signatures, limited vascularization, and batch-to-batch differences, while noting the latest advances in partial/direct reprogramming, biomaterials science, and AI-based phenotypic analysis. Finally, the review will cover the expanding use of iPSC-based systems for high-content screening, functional therapeutic target validation, biomarker discovery, and development, and provide an overview of the future prospects for “clinical-trials-in-a-dish” and precision medicine for AD and other dementia disorders.